Abstract

Polycomb group (PcG) proteins are known to repress developmental genes during embryonic development and tissue homeostasis. Here, we report that PCGF6 controls neuroectoderm specification of human pluripotent stem cells (PSCs) by activating SOX2 gene. Human PSCs with PCGF6 depletion display impaired neuroectoderm differentiation coupled with increased mesendoderm outcomes. Transcriptome analysis reveals that de-repression of the WNT/β-catenin signaling pathway is responsible for the differentiation of PSC toward the mesendodermal lineage. Interestingly, PCGF6 and MYC directly interact and co-occupy a distal regulatory element of SOX2 to activate SOX2 expression, which likely accounts for the regulation in neuroectoderm differentiation. Supporting this notion, genomic deletion of the SOX2-regulatory element phenocopies the impaired neuroectoderm differentiation, while overexpressing SOX2 rescues the neuroectoderm phenotype caused by PCGF6-depletion. Together, our study reveals that PCGF6 can function as lineage switcher between mesendoderm and neuroectoderm in human PSCs by both suppression and activation mechanisms.

Variant Polycomb complexes can have tissue-specific roles during development. Here they show that PCGF6 controls lineage-specification in human PSCs by promoting neuroectoderm differentiation and repressing mesendoderm differentiation via distinct downstream targets.

Details

Title
PCGF6 controls neuroectoderm specification of human pluripotent stem cells by activating SOX2 expression
Author
Lan, Xianchun 1 ; Ding, Song 1   VIAFID ORCID Logo  ; Zhang, Tianzhe 1 ; Yi, Ying 1 ; Li, Conghui 2 ; Jin, Wenwen 1 ; Chen, Jian 3 ; Liang, Kaiwei 2 ; Wang, Hengbin 4   VIAFID ORCID Logo  ; Jiang, Wei 5   VIAFID ORCID Logo 

 Wuhan University, Department of Biological Repositories, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, RNA Institute, Zhongnan Hospital of Wuhan University, Wuhan, China (GRID:grid.49470.3e) (ISNI:0000 0001 2331 6153) 
 Wuhan University, Department of Pathophysiology, School of Basic Medical Sciences, Wuhan, China (GRID:grid.49470.3e) (ISNI:0000 0001 2331 6153) 
 Chinese Academy of Medical Sciences, Chinese Institute for Brain Research (Beijing), Research Unit of Medical Neurobiology, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839) 
 Virginia Commonwealth University, Department of Internal Medicine, Division of Hematology, Oncology, and Palliative Care, Massey Cancer Center, Richmond, USA (GRID:grid.224260.0) (ISNI:0000 0004 0458 8737) 
 Wuhan University, Department of Biological Repositories, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, RNA Institute, Zhongnan Hospital of Wuhan University, Wuhan, China (GRID:grid.49470.3e) (ISNI:0000 0001 2331 6153); Human Genetics Resource Preservation Center of Wuhan University, Wuhan, China (GRID:grid.49470.3e) (ISNI:0000 0001 2331 6153); Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, China (GRID:grid.49470.3e) (ISNI:0000 0001 2331 6153) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2699288884
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.